Clinical trials · Los Angeles, CA
Small Cell Lung Carcinoma clinical trials in Los Angeles
We’re tracking 130 recruiting small cell lung carcinoma studies with a site in or near Los Angeles — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Los Angeles
- NCT06139627Recruiting
Geriatric assessment for older adults with lung cancer getting chemotherapy and radiation
This trial tests whether a special geriatric assessment can help manage side effects for adults aged 60 and older with non-small cell lung cancer who are starting a new treatment plan that includes chemotherapy and radiation. It aims to improve quality of life and treatment outcomes.
Duarte, CaliforniaAges 60 years+ - NCT06172478RecruitingPhase 2
HER3-DXd for advanced solid tumors after prior treatment
This trial tests a new targeted drug called HER3-DXd for people with several types of advanced solid tumors that have stopped responding to standard treatments. The drug is an antibody-drug conjugate, designed to deliver chemotherapy directly to cancer cells that have a protein called HER3 on their surface.
Duarte, CaliforniaAges 18 years+ - NCT04165798Recruiting
Pembrolizumab with or without chemotherapy for stage IV lung cancer
This trial tests whether pembrolizumab alone, or pembrolizumab plus chemotherapy, can treat stage IV non-small cell lung cancer. It may help shrink tumors and improve outcomes by boosting the immune system, with or without added chemotherapy.
Duarte, CaliforniaAges 18 years+ - NCT07619599RecruitingPhase 1
PET Scan to Track Lung Cancer Treatment Response
This study uses a special PET imaging scan to help doctors see how well pembrolizumab (an immunotherapy drug) is working against advanced non-small cell lung cancer. You'll receive the scan along with your regular pembrolizumab treatment and possible radiation therapy to help measure treatment response.
Duarte, CaliforniaAges 18 years+ - NCT06014827RecruitingPhase 2
Targeted radiation and osimertinib for lung cancer with EGFR mutation
This trial tests a new approach for patients with advanced non-small cell lung cancer that has a specific EGFR mutation (Ex19del or L858R) and has started to grow again after at least six months on osimertinib. It combines two types of focused radiation with continued osimertinib to treat only the progressing spots while keeping the rest of the disease under control.
Duarte, CaliforniaAges 18 years+ - NCT06427941RecruitingPhase 1
Study of BGB-B2033 drug for advanced solid tumors
This trial tests a new drug, BGB-B2033, alone or with other treatments, for people with advanced liver, stomach, lung, or germ cell cancers that have not responded to standard therapy. The goal is to see if the drug is safe and works against these tumors.
Duarte, CaliforniaAges 18 years+ - NCT06686771RecruitingPhase 3
Radiation for limited growth in advanced lung cancer on immunotherapy
This trial tests whether giving high-precision radiation to a few spots that are growing during immunotherapy (with or without chemotherapy) can help people with advanced lung cancer. It aims to see if treating these limited areas of resistance can extend the time the cancer stays under control.
Duarte, CaliforniaAges 18 years+ - NCT06287775RecruitingPhase 1/Phase 2
Testing a new drug combo for small cell lung cancer
This trial tests adding a new drug, iadademstat, to standard immunotherapy drugs (atezolizumab or durvalumab) for people with small cell lung cancer that responded to initial treatment. The goal is to see if this combination works better at preventing cancer from returning.
Duarte, CaliforniaAges 18 years+ - NCT06179069RecruitingPhase 1
Study of ZL-1310 for small cell lung cancer
This trial tests a new drug called ZL-1310, alone or with other treatments, for people with small cell lung cancer that has spread (extensive-stage). It aims to see if ZL-1310 can help shrink tumors or slow the disease.
Duarte, CaliforniaAges 18 years+ - NCT04165070RecruitingPhase 1/Phase 2
Stage IV lung cancer trial using pembrolizumab with or without chemotherapy
This Phase 1/2 study tests pembrolizumab (an immune-based cancer treatment) either alone or with chemotherapy in people newly diagnosed with stage IV non-small cell lung cancer (NSCLC). It looks at how well the treatments work and whether they are safe, especially in people who haven’t had treatment yet for metastatic disease.
Duarte, CaliforniaAges 18 years+ - NCT06699212RecruitingPhase 3
Light-activated therapy with immunotherapy for head and neck cancer
This trial tests a new light-activated treatment (ASP-1929) combined with an immunotherapy drug (pembrolizumab) as a first treatment for head and neck cancer that has come back in the same area but has not spread to other parts of the body. It aims to see if this combination works better than standard treatment alone.
Duarte, CaliforniaAges 18 years+ - NCT05789082RecruitingPhase 1/Phase 2
Divarasib for untreated lung cancer with KRAS G12C
This trial studies divarasib to see if it is safe and can shrink or control advanced lung cancer. Participants must have a KRAS G12C mutation and have not had prior treatment for their advanced disease.
Duarte, CaliforniaAges 18 years+ - NCT05672108RecruitingPhase 2
Chemo delivered into lung tumors using a catheter
This trial studies a treatment that delivers chemotherapy directly to lung tumors by placing a catheter into lung blood vessels. It may help people with lung cancer or lung metastases that are growing despite standard treatment, or who cannot tolerate it.
Duarte, CaliforniaAges 18 years+ - NCT06868277RecruitingPhase 3
Comparing two drugs for first-line treatment of advanced lung cancer
This trial tests a new drug called Rilvegostomig against the standard drug pembrolizumab (Keytruda) for people with advanced non-small cell lung cancer that has high levels of PD-L1 protein. The goal is to see which drug works better as a first treatment before any other cancer therapy.
Los Alamitos, CaliforniaAges 18 years+ - NCT05257551Recruiting
Small cell lung cancer data study using tumor and blood samples
This observational study collects information and lab samples from people with extensive-stage small cell lung cancer. It may help researchers understand how patients respond and improve future care, but it usually does not add new treatment for you.
Los Alamitos, CaliforniaAges 18 years+ - NCT05467748RecruitingPhase 1/Phase 2
Study drug combo for advanced lung cancer after PD-1 treatment
This Phase 1/2 trial tests a combination of an EZH2 inhibitor (tulmimetostat) with a PD-1 blocker (pembrolizumab) for advanced non-small cell lung cancer that has stopped responding to prior PD-1 treatment. It may help shrink or control cancer and is mainly aimed at people who have limited treatment options left.
Long Beach, CaliforniaAges 18 years+ - NCT06881784RecruitingPhase 3
Study of a RAS-targeting pill for lung cancer
This trial tests a new daily pill (daraxonrasib/RMC-6236) for people with advanced non-small cell lung cancer that has a specific RAS mutation. It's for those who have already tried 1 or 2 previous treatments, including immunotherapy and chemotherapy.
Long Beach, CaliforniaAges 18 years+ - NCT06875310RecruitingPhase 3
Study of adagrasib plus pembrolizumab plus chemotherapy for KRAS G12C lung cancer
This trial tests if adding the targeted drug adagrasib to standard immunotherapy and chemotherapy helps people with a specific KRAS G12C mutation in non-squamous non-small cell lung cancer that has spread. It is for people who have not had previous treatment for advanced disease.
Long Beach, CaliforniaAges 18 years+ - NCT07140016RecruitingPhase 1
Study of gilteritinib for advanced ALK-positive lung cancer
This trial tests an oral drug called gilteritinib for people with advanced ALK-positive non-small cell lung cancer that has progressed after prior ALK inhibitor treatment. It aims to see if gilteritinib can help when other treatments have stopped working.
Fullerton, CaliforniaAges 18 years+ - NCT06216301RecruitingPhase 3
Electric fields with immunotherapy and chemo for advanced lung cancer
This trial tests adding a device that delivers electric fields (Tumor Treating Fields) to standard immunotherapy and chemotherapy for people with advanced non-small cell lung cancer that has not been treated before. It may help slow tumor growth.
Fullerton, CaliforniaAges 18 years+ - NCT05271292RecruitingPhase 1/Phase 2
Chiauranib for advanced cancers that returned or won’t respond
This Phase 1/2 study tests chiauranib in people with advanced solid cancers (including small cell lung cancer) that have come back or no longer respond to standard treatments. It aims to find a safe dose and see whether the treatment can help shrink tumors.
Fullerton, CaliforniaAges 18 years+ - NCT06758401RecruitingPhase 3
Sigvotatug vedotin plus pembrolizumab for advanced lung cancer with high PD-L1
This trial tests a new combination of two study medicines for people with advanced non-small cell lung cancer that has high levels of PD-L1 protein. The goal is to see if adding sigvotatug vedotin to pembrolizumab works better than pembrolizumab alone.
Fullerton, CaliforniaAges 18 years+ - NCT07144280RecruitingPhase 3
Study of a new drug vs docetaxel for advanced lung cancer
This trial tests a new experimental drug called PF-08046054/SGN-PDL1V against a standard chemotherapy (docetaxel) for people with a type of advanced lung cancer that has PD-L1 protein on at least 1% of tumor cells and has progressed after prior treatments. The goal is to see if the new drug works better or has fewer side effects.
Fullerton, CaliforniaAges 18 years+ - NCT04402788RecruitingPhase 2/Phase 3
Radiation added to immune therapy for extensive small cell lung cancer
This trial tests whether adding radiation therapy to standard immune therapy (atezolizumab) after initial chemo can help people with extensive-stage small cell lung cancer live longer and control the cancer better. You must have a good response (partial response) or stable disease after initial treatment, plus several lab/imaging checks to confirm safety.
Orange, CaliforniaAges 18 years+
Hear when a new Small Cell Lung Carcinoma trial opens near Los Angeles, CA
We’ll email you when one opens near Los Angeles, CA — at most once a week, no account needed, unsubscribe anytime.
Small Cell Lung Carcinoma trials in other cities
Where these studies are running near Los Angeles
Institutions with a site for the recruiting small cell lung carcinoma studies listed above.
- City of Hope Comprehensive Cancer Center · 13 studies
- City of Hope Orange County Lennar Foundation Cancer Center · 3 studies
- Providence Medical Foundation · 3 studies
- Providence St. Jude Medical Center · 3 studies
- St. Joseph Heritage Healthcare · 2 studies
- University of California, Irvine Medical Center / UC Irvine Health · 2 studies
- Cancer and Blood Specialty Clinic
- City of Hope
What taking part in a small cell lung carcinoma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting small cell lung carcinoma studies in California.
Common questions
- Are there small cell lung carcinoma clinical trials near Los Angeles?
- Yes. We're currently tracking 130 recruiting small cell lung carcinoma studies with a site near Los Angeles, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a small cell lung carcinoma study near Los Angeles?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Los Angeles to take part?
- Not necessarily. These studies have a site near Los Angeles, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a small cell lung carcinoma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New small cell lung carcinoma studies open near Los Angeles regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.